Pharvaris N.V.
Late-stage biopharma developing oral therapies for hereditary angioedema (HAE).
PHVS | US
Overview
Corporate Details
- ISIN(s):
- NL00150005Y4
- LEI:
- Country:
- United States of America
- Address:
- J.H. OORTWEG 21, 0 LEIDEN
- Website:
- https://pharvaris.com/
- Sector:
- Manufacturing
Description
Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare, bradykinin-mediated diseases, with a primary focus on hereditary angioedema (HAE). The company is advancing a pipeline of novel, oral bradykinin B2 receptor antagonists. Its lead product candidate, deucrictibant, is in pivotal Phase 3 studies for both the on-demand (acute) and prophylactic (preventative) treatment of HAE attacks. Pharvaris aims to provide patients with an effective, well-tolerated oral therapy as a convenient alternative to injectable treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Pharvaris N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharvaris N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharvaris N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
